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ABSTRACT 
The incidence of life-threatening invasive fungal infections in 
immunocompromised patients has increased dramatically in 
recent years. Candida spp other than C. albicans are increas- 
ingly being isolated, and Aspergillus infections also are on the 
increase, as well as infections due to previously uncommon 
organisms. It is likely that this phenomenon is multifactorial in 
origin, although the extensive use of antifungal prophylaxis may 
have played a role, especially for the emergence of non-albi- 
cans Candida. Amphotericin B remains the antifungal agent 
with the broadest spectrum of action available and is thus the 
standard treatment for immunocompromised patients with 
proven or suspected fungal infections, especially aspergillosis. 
However, its potential for nephrotoxicity limits its usefulness. 
Lipid formulations of amphotericin B may allow therapy to be 
administered with reduced renal toxicity. Three different lipid 
formulations of amphotericin B currently are available. These 
compounds have different pharmacokinetic properties and 
seem to achieve higher serum or tissue concentrations than 
amphotericin B. This statement is based on animal models and 
scattered human data. At present, there are no studies com- 
paring the lipid formulations with each other and only a few 
randomized trials comparing them with conventional ampho- 
tericin B. However, a number of open clinical trials and com- 
passionate-use protocols suggest that lipid-based forms of 
amphotericin B can achieve good response rates with minimal 
toxicity in patients with a variety of invasive mycoses, includ- 
ing those who have proved refractory or intolerant to previous 
therapy with conventional amphotericin B. Unfortunately, the 
cost of these compounds remains high and may represent a 
limiting factor to their use. 
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The number of patients undergoing potentially life-saving 
chemotherapy for neoplastic diseases has increased dra- 
matically in recent years. Unfortunately, so has the inci- 
dence of life-threatening invasive fungal infections 
occurring in these patients. l-3 This is especially true for 
recipients of bone marrow transplants (BMTs). Based on 
autopsy studies, it appears that the successful outcome 
of up to a quarter of all BMTs carried out is jeopardized 
by such infections.* Moreover, the variety of pathogenic 
fungi observed in this setting is increasing, with the emer- 
gence of previously uncommon organisms.5 Questions 
of how to manage such patients remain problematic, for 
several reasons. First, it is frequently difficult to confirm 
a fungal infection until late in the course of the disease; 
second, some organisms have intrinsic or acquired resis- 
tance to antifungal agents; third, there is a risk of renal 
and other drug-related toxicity, particularly in BMT 
patients receiving concomitant therapy for graft-versus- 
host disease (GVHD); and finally, all therapeutic and pro- 
phylactic efforts can be frustrated by the absolute inability 
of the patient to produce an adequate immunologic 
response. The clinical approach to mycoses in BMT 
patients and the general approach to antifungal therapy 
in cancer patients recently have been reviewed.3s6 This 
article reviews the epidemiology and the etiology of fun- 
gal infections in cancer patients, and the potential ther- 
apeutic role of lipid formulations of amphotericin B in 
these patient populations. 
INCIDENCE AND MORTALITY OF INVASIVE 
FUNGAL INFECTIONS 
According to a large American study,’ the rate of inva- 
sive fungal infections among hospital patients approxi- 
mately doubled between 1980 and 1990, increasing from 
2.0 to 3.8 per 1000 discharges, and the incidence of noso- 
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Table 1. Correlation between Clinical Subtype and Outcome in 
129 Bone Marrow Transplant Patients with Non-Candida Fungal 
Infection 
Dead 
Related Unrelated 
Alive to infection to Infection 
Type of Infection n = 129 n = 23 (18%) n = 69 (53%) n = 37 (29%) 
Minor skin or 
soft iissue 6 2 (33) 0 4 (67) 
Single organ 
or site 59 12 (20) 24 (41) 23 (39)+ 
Disseminated 54 3 (6) 45 (83) 6 (1 I)+ 
Isolated fungemia 10 6 (60) 0 4 (40) 
*Among patients who died of their fungal infection, there were significantly more 
deaths in those with disseminated infection compared to those with single 
organ or single site infection (P < 0.0001). 
‘Among patients who died of causes other than their fungal infection, there was 
no significant difference in numbers of deaths between those with disseminated 
infection and those with single organ or single site infection (P = 0.68). 
(Adapted from Morrison et aLg) 
comial candidemia alone increased fivefold. Similar results 
have been reported in Europe, with one large autopsy 
study showing an increase in frequency from 1.6% in the 
period from 1978 to 1982 to 4.1% in 1988 to 1992.* 
Among BMT patients, an American study revealed an inci- 
dence of fungal infections of between 15% and 25%.* Fur- 
thermore, although they are infrequently the cause of the 
first febrile incident during neutropenia, fungal pathogens 
have been reported to account for almost half of all super- 
infections in BMT patients.’ 
The mortality rates resulting from invasive fungal 
infections are truly frightening, since rates as high as 40% 
overall and 60 to 85% for patients with invasive aspergiJIo- 
sis have been reported. In an American study involving 
1186 BMT patients, 106 of 129 BMT patients with non- 
Table 2. Host Factors Associated with Increased or Possibly 
Reduced Risk of Invasive Fungal Infections in Granulocytopenic 
Patients 
Increased risk 
Protracted granulocylopenia 
Corticosteroid therapy 
Broad-spectrum antibiotics 
Relapsed neoplastic disease 
Hematologic neoplasia 
Previous invasive pulmonary aspergillosis 
Central venous catheter 
Total body irradiation 
Allogeneic BMT, especially with 
T-cell depletion 
GVHD 
Possibly reduced risk 
Solid tumors 
Remission of neoplastic disease 
Recovery from granulocytopenia 
Spontaneous 
Related to recombinant hematopoietic cytokines* 
Related to stem cell reconstitution* 
Related to granulocyte transfusion* 
*Investigational. 
(Adapted from Walsh et al and Viscoli et al,“‘,“) 
Candida fungal infections died, including 69 (53%) whose 
death was directly associated with the fungal infection, 
despite aggressive antifungal therapy.” In this study there 
also was a strong correlation between the extent of vis- 
ceral involvement of the infection and the outcome, with 
83% of patients with disseminated disease dying of their 
infection compared to 43% of those with infection 
located at a single organ or site (P < 0.0001) (Table 1). 
In contrast, there was no significant difference between 
the numbers of patients with disseminated or nondis- 
seminated fungal disease who died from causes other 
than their fungal infection, thus showing the indepen- 
dent role attributable to the fungal infection in causing 
death in this patient population. Cause-specific mortality 
rates were found to be highest for Aspergillus, Chrysospo- 
rium, Fusarium, Mucor, and Scopulariopsis, all pathogens 
with a high potential for invasive disease and dissemi- 
nated infectiom9 
RISK FACTORS 
There are multiple reasons for the increase in incidence 
of invasive fungal infections in cancer patients; primarily, 
the increased intensity of chemotherapy employed in 
these patients (Table 2).l” In BMT patients in particular, 
the effect of the conditioning regimen associated with the 
prolonged use of immunosuppressive agents for the pre- 
vention and treatment of GVHD (especially in patients 
receiving allogeneic BMT from mismatched relatives or 
from matched unrelated donors) may be devastating. 
Moreover, there is a whole series of additional host fac- 
tors associated with increased risk, including the use of 
broad-spectrum antibiotics, indwelling catheters, age, life 
style and hobbies, and previous infectious history (includ- 
ing infections developed before and after the diagnosis 
of cancer).” The resulting multifactorial deficit in the 
anti-infective defenses allows some of the less common 
opportunistic pathogens to take hold, as well as those 
more commonly seen. 
ETIOLOGY OF MYCOSES IN CANCER PATIENTS 
Although Candida and Aspergillus spp remain the most 
commonly identified pathogens in invasive fungal dis- 
ease, more unusual organisms increasingly are being iso- 
lated.2,5 Candida albicans still remains the most 
frequently reported of the Candida spp as the cause of 
disease in cancer patients,” even if other types of Can- 
dida (so called non-albicans strains) are reported with 
increased frequency and sometimes represent the most 
frequently isolated species of Candida (Table 3),13,‘* with 
an increased likelihood of intrinsic or acquired resistance 
to the most widely used antifungal agents.2,‘2,‘3z’5 In a 
prospective study of candidemia in a miscellaneous group 
of immunocompromised patients, the percentage of 
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Table 3. Predominant Candida Pathogens in Oncology Patients 
during Different Decades 
195os-1970s 1980s 1990s 
c. a/bicans C. albicans 
C. tropicalis 
C. albicans 
C. tropicalis 
C. glabrata 
C. krusei 
C. lusitaniae 
C. parapsilosis 
(From Wingard.2) 
infection caused by non-albicans Candida spp (in 
decreasing order: C. glabrata, C. tropicalis, C. parapsilo- 
sis, C. krusei, C. Zusitaniae, and C. pseudotropicalis) 
increased from 40% to 53% between June 1990 and June 
1994, with increases seen in all four medical centers par- 
ticipating in the study.13 In a large surveillance study per- 
formed by the Invasive Fungal Infection Group of the 
European Organization for Research and Treatment of 
Cancer (EORTC), the shift from C. albicans to non-albi- 
cans Candida as cause of candidemia was more relevant 
in patients with hematologic malignancies than in those 
with solid tumors. Among patients with hematologic 
malignancies, a multivariate analysis showed that the 
occurrence of non-albicans candidemia was significantly 
correlated with the underlying disease (acute leukemia 
with respect to lymphoma) and with the administration 
of antifungal prophylaxis (mainly azole drugs, but also 
intravenous amphotericin B). Among patients with solid 
tumors, only neutropenia was significantly associated with 
non-albicans candidemia.15 The trend toward the emer- 
gence of non-albicans strains also has been confirmed in 
a recent study at the M.D. Anderson Cancer Center in 
Houston, Texas, USA.16 At least in part, the emergence of 
non-albicans strains might be correlated with the wide- 
spread and prolonged use of antifungal prophylaxis, 
which, while successfully knocking out sensitive organ- 
isms, has allowed other pathogens or more or less resis- 
tant strains to emerge. However, the situation is probably 
more complicated than that, since the epidemiologic 
impact of fluconazole has been noted mostly at single 
centers, but not confirmed either in prospective multi- 
center trials or in other single centers observations (E. 
Castagnola. Personal communication).‘9-21 Therefore, the 
shift in the etiology of Candida infections is probably 
multifactorial in origin.** 
The rate of Aspergillus infection varies among insti- 
tutions as a result of patient selection and differences in 
therapeutic regimens as well as the presence or absence 
of contaminated ventilation systems or hospital con- 
struction work.2.23 In general, invasive Aspergillus infec- 
tions are on the increase in patients treated for acute 
leukemia or undergoing BMT, with an incidence as high 
as 25% in some allogeneic BMT populations, such as those 
receiving BMT from mismatched relatives or from 
matched unrelated donors.24 The study in Germany gave 
more insight into this problem and confirmed that there 
is a trend toward a decreasing incidence of Candida 
infection and an increasing incidence of infections due 
to filamentous fungi among immunocompromised 
patients.* The incidence of invasive infections with pre- 
viously uncommon fungal pathogens, such as Fusarium, 
Trichosporon, Alternaria, and species belonging to 
Zygomycetes (e.g., Rhizopus, Cunninghamella, and 
Absidia spp), is clearly increasing, especially in patients 
with profound and prolonged neutropenia.2,j*s~10~2j In a 
study performed in a single American hospital9 investi- 
gators reported non-Candida fungal infections occurring 
in 1 l%, 70% of which were Aspergillus infections, but no 
fewer than I6 other species were identified (Table 4). 
However, these findings might just be representative of 
local situations and cannot necessarily be extrapolated 
Table 4. Non-Candida Pathogens among BMT Patients with Disseminated Fungal Infection or Fungemia 
fungal /so/ate 
Minor Skin Sing/e Organ 
& Soft Tissue or Single Site 
(n = 7) (n = 61) 
Disseminated 
infection 
(n = 58) 
Isolated 
Fungemia 
(n = 12) 
Total 
n = 70 (%) 
Acremonium 
Alternaria 
Aspergitius 
Chrysosporium 
Curvularia 
Fusarium 
Hansenula 
Histoplasma Malassezia 
Mucor 
P enicillium 
Phialophora 
Phoma 
Rhodotorula 
Saccharomyces 
Scopulariopsis 
Trichosporon 
(From Morrison et al.9) 
- - 3 3 (2) 
- 6 - 6 (4) 
5 49 43 - 97 (70) 
- - 1 - 1 (1) - 1 - 1 (1) 
- 2 7 1 10 (7) 
- - 1 1 (1) 
- - 3 3 (2) - - 1 1 (1) 
- 1 2 - 3 (2) 
- - 2 2 (1) 
- 1 - 1 (1) 
1 - - 1 (1) 
- - 1 1 (1) 
- 1 - 1 2 (1) 
1 - 1 - 2 (1) 
- 1 2 3 (2) 
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to other hospitals. Invasive trichosporosis, fusariosis, and 
mucormycosis all are associated with a poor prognosis 
and high mortality rates. 
Resistance in Candida Species 
The concept of drug resistance as applied to antifungal 
drugs is not clear. Indeed, drug resistance can be con- 
sidered either as clinical failure or as a drug minimum 
inhibitory concentration (MIC) that is higher than the 
serum concentration readily obtainable in vivo with the 
usual dosage of a given drug. Unfortunately, therapeutic 
failures and successes can be obtained with pathogens 
that are in vitro-resistant or sensitive (i.e., regardless of the 
MIC for the pathogen). The clinical scenario that can be 
envisaged includes (1) the development of resistance dur- 
ing therapy in an isolate that was initially sensitive to a 
given drug, (2) the selection among a fungal population 
of a strain or species that is intrinsically resistant to a 
given drug, or (3) the acquisition de novo of a pathogen 
that is intrinsically resistant.26 Simply to identify resis- 
tance with clinical failure can be misleading. For exam- 
ple, in a recent study of fluconazole in the management 
of candidemia in immunocompromised patients, catheter 
change was found to be a crucial factor for response to 
treatment. In these cases, failure showed little association 
with MICs of fluconazole.27,28 Despite these limitations, 
it is clear that resistance to azole drugs (and especially to 
fluconazole, the most widely used antifungal drug in the 
past 6 years) can occur and is probably increasing.29-33 
However, the development of fluconazole resistance has 
been uncommon in short-term therapy, such as that 
administered to cancer patients,“* whereas development 
of resistance during therapy in strains that were formerly 
susceptible has been well described in patients with 
acquired immunodeficiency syndrome (AIDS) receiving 
multiple and prolonged courses of low-dose fluconazole 
for the treatment of oropharyngeal candidiasis.35 The sec- 
ond type of resistance (i.e., intrinsic resistance) to flu- 
conazole is common in C. krusei, with a much higher in 
vitro MIC compared to most C. albicans iso1ates.l’ Can- 
dida glabrata infections also tend to require much higher 
doses of fluconazole for their successful management, to 
the extent that some strains should probably be consid- 
ered intrinsically resistant. l8 If these pathogens are pre- 
sent in a mixed population of Candida strains, they could 
be selected by fluconazole use. As recently pointed out 
by Rex et al, z6 it appears that a MIC of fluconazole (as 
evaluated by the National Committee for Clinical Stan- 
dards [NCCLS] methodology) around 16 pg/mL is pre- 
dictive of a poor response to a dosage of fluconazole of 
100 mg per day, and that a MIC higher than 64 pg/mL pre- 
dicts a poor response to dosages as high as 400 to 800 
mg per day. Often, strains resistant to fluconazole also 
are resistant to other azoles29 In patients with serious 
Candida infections, combination therapy with ampho- 
tericin B and flucytosine may be synergistic, but carries 
a relatively increased risk of flucytosine-related toxicity.36 
Although amphotericin B remains the antifungal agent 
with the broadest spectrum of action available, labora- 
tory studies have identified amphotericin B-resistant 
strains of C. albicans, C. glabrata, C. guilliermondii, C. 
krusei, C. lusitaniae, and C. neoformans.29z32,37-40 Fur- 
thermore, the duration of prior amphotericin B therapy 
has been shown to be directly correlated to the mini- 
mum lethal concentration of amphotericin B against Can- 
dida isolates occurring during breakthrough 
candidemia.13 
Resistance in Asperglllus Species 
Aspergillus spp are intrinsically resistant to fluconazole. 
In contrast, many isolates show in vitro susceptibility to itra- 
conazole. However, bioavailability of the oral form of itra- 
conazole varies among individuals and also may be reduced 
as a result of damage to the intestinal epithelium caused 
by intensive chemotherapy *l In theory, plasma itracona- 
zole levels should be closely monitored to ensure that 
appropriate MICs are achieved. Clinical experience indi- 
cates that amphotericin B generally is active against 
Aspergillus spp. In vitro studies have identified strains of 
A. nidulans, A.flavus, and A. conicus that are resistant to 
amphotericin B, but there is no firm evidence to date that 
in vitro susceptibility is related to the clinical outcome in 
aspergillosis.38 The problem is more likely to be inade- 
quate dosage because of toxicity problems, particularly 
nephrotoxicity, and severity of the underlying immuno- 
suppression. Flucytosine is inactive against filamentous 
fungi like Aspergillus spp, although it is sometimes rec- 
ommended in combination with amphotericin B.36 
Resistance in Other Pathogenic Fungi 
Most of the more unusual fungal pathogens referred to 
above are resistant to azole therapy but may respond to 
treatment with amphotericin B. However, both Tri- 
chosporon spp and Fusarium spp have been reported to 
have intrinsic resistance to amphotericin B.30x38 Many iso- 
lates of Pseudallescheria boydii and Trichosporon 
beigelii are resistant to amphotericin B, with an in vitro 
MIC well over 2 mg/L,25 and it has been suggested that 
infections with these organisms are best treated with 
alternative antifungal agents.29 
MANAGEMENT OF INVASIVE FUNGAL INFECTION 
Fluconazole 
Fluconazole is a triazole antifungal drug that can be 
administered once a day either orally or intravenously. 
Dosages commonly used are 6 to 12 mg/kg per day in 
children and 400 to 1200 mg per day in adults. Dosages 
of 19 mg/kg per day in children and 1600 mg per day in 
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adults have been tolerated. The drug, which diffuses read- 
ily in tissues, is eliminated unmodified by the renal route. 
The spectrum of action includes many strains of Can- 
dida (with the exception of C. kruzei and C. glabrata), 
Cryptococcus spp and T beigelii. Unfortunately, flucona- 
zole is not active against filamentous fungi, such as 
Aspergillus. At therapeutic doses, the most frequently 
reported side effect is hepatotoxicity, which usually dis- 
appears at the end of treatment.3,6 A large comparative 
clinical trial in non-neutropenic immunocompromised 
patients showed that fluconazole was as effective as 
amphotericin B deoxycholate in the treatment of can- 
didemia.27 Since, in these patients, candidemia is fre- 
quently correlated with indwelling catheter colonization, 
catheter removal is usually considered mandatory.42 
Itraconazole 
Itraconazole is another triazole antifungal drug that can 
be administered once a day, although only by the oral 
route. The dosage is 7 mg/kg per day in children and 400 
mg per day in adults. Less clinical experience is available 
for the use of itraconazole at higher doses, although the 
drug is likely to be well tolerated. There is no intravenous 
formulation of itraconazole currently available. Absorp- 
tion by the oral route is erratic and the drug needs to be 
administered with meals (which is nearly impossible in 
patients with severe stomatitis, who are unable to swal- 
low any food). A potentially effective, although empirical 
way of using itraconazole is in sequential therapy, in 
patients with aspergillosis who have completed an ade- 
quate course of amphotericin B (either deoxycholate or 
lipid-based) and who are able to swallow food and med- 
ication. A new formulation of itraconazole associated with 
cyclodextrine seems to be associated with improved 
bioavailability and could be useful for the therapy of doc- 
umented fungal infections in patients able to swallow 
medications.3z6 
Amphotericin B Deoxycholate 
Although the antifungal activity of amphotericin B is 
probably concentration-dependent,43 relation between 
serum and tissue concentrations, on the one hand, and 
clinical efficacy and toxicity, on the other, are unclear. 
Nevertheless, in the clinical setting, amphotericin B 
remains the drug with the broadest antifungal activity 
and the lowest risk of development of secondary resis- 
tance. Amphotericin B is not absorbed by the oral route 
and must be administered intravenously to achieve ther- 
apeutic blood levels. Orally, it exerts a topical activity that 
can be important for reducing intestinal colonization and 
for treating oropharyngeal and gastrointestinal candidia- 
sis. Intravenously, the most appropriate dose of ampho- 
tericin B is not established. It is usually administered once 
a day at dosages of 0.5 to 1.5 mg/kg per day (depending 
on the pathogen involved and the clinical circumstances) 
in 5% dextrose in water, in an infusion lasting from 1 to 
6 hours (most often 4 hours). Classic teaching suggests 
that the dosage should be increased slowly, by 0.1 mg/kg 
daily, but in case of severe infections or in high-risk 
patients, full dosages must be administered from the first 
or second day of treatment. In general, amphotericin B 
should be administered through a central venous access. 
If such a device is not available, heparin (1000 U) should 
be added to the solution, to reduce the risk of phlebitis. 
More than the early toxic reactions (that are rarely severe 
enough to warrant treatment discontinuation, but that 
can often limit the daily amount of drug that can be 
administered), the major drawback of amphotericin B 
therapy is its renal toxicity. Although this is manageable 
to some extent by the use of prior fluid and salt loading, 
it still remains a serious problem. In patients who are 
already receiving other nephrotoxic agents, such as 
cyclosporine, the risk is greatly increased and can create 
a real clinical dilemma: to reduce the immunosuppres- 
sive treatment, thus increasing the risk of GVHD, or to 
reduce the dose, thus increasing the risk of treatment 
failure? In documented fungal infections with no alter- 
native to amphotericin B, lipid formulations of ampho- 
tericin B may help to resolve this dilemma. 
Lipid Formulations of Amphotericin B 
When dealing with the lipid formulations of amphotericin 
B, the main problems are (1) the scarcity of pharmaco- 
kinetic data; (2) the small number of comparative clini- 
cal trials with amphotericin B deoxycholate, especially 
in documented infections; (3) the absolute absence of 
comparative studies between each of the lipid formula- 
tions; and (4) the fact that, at the time of this writing, 
some studies have been published in abstract form, which 
means that little information about the statistical method- 
ology is available and the results are often preliminary. 
Owing to the shortage of data, there is the risk that the 
fight for the market share will depend largely on which 
product is the first to the market and on which prod- 
uct’s marketing campaign is the most successful in manip- 
ulating physicians’ preferences.** While waiting for 
reliable studies, physicians must base their decisions 
about which would be the best compound in each indi- 
vidual patient with each type of infection more on exper- 
imental animal models than on data from randomized, 
controlled trials in humans. 
As recently reviewed, 45 three different lipid formu- 
lations of amphotericin B presently are available on the 
market in most European countries and in the United 
States: liposomal amphotericin B (LAMB), amphotericin B 
colloidal dispersion (ABCD), and amphotericin B lipid 
complex (ABLC). These vary considerably in terms of 
their structure and bioavailability compared to deoxy- 
cholate amphotericin B (DAMB) (Table 5). Their most 
important feature is that they are less nephrotoxic and 
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Table 5. Structure and Pharmacokinetics of Three Lipid Formulations of Amphotericin B 
Lipid Formulation Lipid Configuration Size (nm) Lipids Mean C,,, in pg/mL (dose)* 
AbelcetB (amphotericin 
B lipid complex) Ribbon-like 1,600-l 1,000 DMPC, DMPG Decreased 
0.27 (1 .O mg/kg) 
1 .I 0 (2.5 mg/kg) 
AmphociVAmphotecB 
(amphotericin B colloidal 
dispersion) Disk-like 120-l 40 Cholesteryl sulphate Decreased 
0.84 (0.5 mg/kg) 
2.19 (1 .O mg/kg) 
2.53 (1.5 mg/kg) 
AmBisomeR (liposomal Small unilamellar 
amphotericin B) vesicle (liposome) 80 Hydrogenated soy PC, DSPG Increased 
7.30 (1 .O mg/kg) 
17.20 (2.5 mg/kg) 
57.60 (5.0 mg/kg) 
AbelcetB, The Liposome Company, Princeton, New Jersey: Amphotec, Sequus Pharmaceuticals, Inc., Menlo Park, California; AmBisome, Fujisawa Healthcare Inc., 
Deerfield, Illinois, and NeXstar Pharmaceuticals, Inc., Boulder, Colorado. 
Decreased or increased in reference to values for conventional amphotericin B. 
DMPC = dimyristoyl phosphatidylcholine; DMPG = dimyristoyl phosphatidylglycerol; PC = phosphatidylcholine; DSPG = distearoyl phosphatidylglyceroi. 
(Adapted from Hiemenz and Walsh.so) 
safer than DAMB, even in patients with renal failure result- 
ing from previous courses of amphotericin B or other 
nephrotoxic drugs. However, this might not be true for 
infusion-related events. Indeed, in a recent randomized 
study of empirical antifungal therapy, these side effects 
were more common with ABCD than with DAMB.*” It 
should be noted that what is known about the pharma- 
cokinetics of the lipid compounds of amphotericin B is 
based on measurements of the total amount of drug, with 
no estimate of whether the drug is free or bound.*’ 
Pharmacokinetics and Tolerability 
All lipid compounds are able to concentrate in the retic- 
uloendothelial system, but present different pharmaco- 
kinetic profiles. 47-50 Amphotericin B lipid complex has a 
short plasma half-life and seems to achieve the highest 
concentrations in the liver, spleen, and lungs, with lower 
levels achieved in plasma. Amphotericin B colloidal dis- 
persion also has a short half-life and is concentrated in 
the liver, whereas LAMB is concentrated in the liver, 
spleen, and at lower concentrations, lungs. Moreover, 
LAMB shows a rate of uptake by the reticuloendothelial 
system that is much slower than that by the other com- 
pounds, which provides a reason for its longer half-life 
and higher blood levels. Some data seem to suggest the 
existence of a correlation between the improved phar- 
macokinetics of these compounds and their clinical effec- 
tiveness. Indeed, in an animal model, LAMB recently has 
been shown to achieve cerebral concentrations that are 
significantly higher than those obtained with DAMB or 
the other lipid formulations,51 and surprisingly, a corre- 
lation between tissue concentrations and efficacy has 
been observed with an in vivo model of murine crypto- 
coccosis.52 All three compounds produce low kidney 
concentrations of drug, which is probably one of the rea- 
sons explaining their reduced renal toxicity. In all but 
one of the experimental and clinical studies that have 
been performed,46 lipid compounds have proved to be 
less toxic and to have a maximum tolerated dose that is 
higher than that of DAMB.53-59 In an American multicen- 
ter, open-label, emergency-use protocol,59 ABLC (admin- 
istered at a median dose of 4.9 mg/kg/d) was found to 
be well tolerated overall. Although 9% of the patients had 
treatment discontinued because of adverse events, there 
was a significant fall in serum creatinine levels during 
therapy (P = 0.03).59 Among patients with prior ampho- 
tericin B-induced nephrotoxicity or renal dysfunction, 
the decrease in serum creatinine was particularly pro- 
nounced (P = 0.001). Furthermore, the subgroup of 
patients with baseline serum creatinine levels of 2.5 
mg/dL showed the most significant decrease of all, from 
the first week through the sixth week of therapy (P < 
0.0001). Studies using LAMB indicate that it is well tol- 
erated, even in patients who have already experienced 
adverse effects on DAMB. 55,56 For example, among 116 
neutropenic patients who could not tolerate or did not 
respond to DAMB, adverse effects during LAMB treatment 
were infrequent, and there was no significant impact on 
renal function. Five patients experienced acute reactions, 
23 had reversible hepatic dysfunction, and 17 had hyper- 
natremia.57 Similar tolerability has been shown for ABCD 
in a trial involving 168 patients with documented or pre- 
sumed invasive mycosis in whom prior DAMB had proved 
ineffective or toxic.58 Even though the dose was increased 
to as high as 6 mg/kg per day in some patients and the 
mean cumulative dose was 4 mg/kg per day, serum cre- 
atinine values remained unchanged from baseline to the 
end of the study, with a mean fall of 0.02 mg/dL. In gen- 
eral, the three lipid compounds seem to be equivalent in 
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Table 6. Response to Amphotericin B Lipid Complex According Table 7. Response to Treatment in Patients with invasive 
to Type of Infection in the Open-Label Emergency-Release Candidiasis: Results of a Prospective Randomized Trial of 
Protocol Amphotericin B Lipid Complex versus Amphotericin B 
Type of Infection 
Candidiasis 
Aspergillosis 
Zygomycosis 
Fusariosis 
(From Walsh et ai.59) 
Clinical Response (%) 
65/91 (71) 
55/l 30 (42) 
17/24 (71) 
9/i 1 (82) 
Response 
to Treatment ABLC Amphotericin B 
Overall 81/i 24 (65%) 43/70 (61%) 
According to underlying condition 
Hematologic 
P-Value 
0.642 
terms of renal toxicity. Infusion-related toxicity also may 
be a problem with the lipid compounds. Although there 
are no comparative data, the clinical experience suggests 
that LAMB and ABLC are well tolerated (with some pos- 
sible advantage for LAMB over ABLC).“’ Amphotericin B 
colloidal dispersion seems to have the same or even more 
immediate adverse effects than DAMB,*’ and should prob- 
ably be given with premeditation. 
malignancy 14/28 (50%) 2/l 2 (17%) 0.079 
Solid tumor 24/32 (75%) 17/25 (68%) 0.570 
Major surgery 16/21 (76%) 7/i 0 (70%) 1.000 
Other 27/43 (63%) 17/23 (74%) 0.421 
ABLC = amphotericin B lipid complex. 
(From Anaissie et aL6*) 
Effkacy 
among the 14 courses given for proven infection, includ- 
ing complete responses in all five patients with confirmed 
Candida infections. In an open-label, compassionate-use 
trial of ABCD in patients who had failed to respond to 
DAMB or who had renal insufficiency, 19 (58%) of 33 evalu- 
able patients with candidiasis responded to ABCD at a 
dose of 3 mg/kg per day58 
Several noncomparative studies have been carried out to 
assess the benefits of administering lipid formulations of 
amphotericin B to patients with proven refractory myco- 
sis or who were intolerant to previous antifungal therapy, 
most of which consisted of DAMB. 
Candidiasis. Results of the American emergency-use pro- 
tocol with ABLC showed a complete or partial response 
rate of 71% among the evaluable patients with dissemi- 
nated candidiasis (Table 6).59 A separate analysis for the 
BMT patients in the study has been performed.61 Among 
the 59 such patients evaluable for response to ABLC, 20 
had proven candidiasis, 70% of whom responded clinically 
to therapy A prospective, randomized, multicenter trial 
also has been carried out to compare ABLC (5 mg/kg/d) 
with DAMB (0.6-l mg/kg/d) for the treatment of invasive 
candidiasis.62 In this study, around two thirds of patients in 
each treatment group responded (Table 7). Although the 
frequency of adverse events was similar in the two groups, 
patients receiving ABLC developed less nephrotoxicity 
than those receiving amphotericin B. Pediatric patients 
also appear to respond well to ABLC, as shown in a small 
study carried out at the National Cancer Institute in 
Bethesda, Maryland, USA. 63 In this study, six children with 
hepatosplenic candidiasis were treated with ABLC at a 
dose of 2.5 mg/kg per day. All five patients who were evalu- 
able responded to ABLC, with resolution of lesions as deter- 
mined by computed tomography and magnetic resonance 
imaging. In a study in the United Kingdom, 49 adult 
patients with hematologic malignancies were treated with 
ABLC 5 mg/kg per day for presumed or proven fungal 
infection, following failure of previous antifungal therapy 
or renal dysfunction. 64 The overall response rate was 64% 
among 39 evaluable empirical courses of ABLC and 71% 
Aspergillosis. Response rates of up to 77% have been 
achieved in various studies in patients with invasive 
aspergillosis who were treated with lipid formulations of 
amphotericin B (Table S).22.57-59,61-67 In the American 
open-label study of ABLC, there was a clinical response 
rate of 42% overall (see Table 6).59 In a study in which 
LAMB was given to 116 neutropenic patients for 133 
episodes of suspected or confirmed fungal infection, there 
was an overall response rate of 61%. Among the 17 
patients with proven aspergillosis in this study, 13 (77%) 
responded to LAMB even though 11 of them had failed 
to respond to DAh4B. 57 In the open-label, compassionate- 
use protocol with ABCD, clinical responses were seen in 
11 (34%) of 32 aspergillosis patients who were refrac- 
tory or intolerant to DAMB.58 In another study, a group 
of 82 patients with proven or probable aspergillosis 
treated with ABCD was compared with an historic con- 
trol group of 261 patients treated with DAMB.22 The 
Table 8. Clinical Response to Various Lipid-Based Forms of 
Amphotericin B in Patients with Invasive Aspergillosis Refractory 
or Intolerant to Conventional Amphotericin B 
Lipid-Based Form Number 
of Amphotericin B of Patients Response* (%) Reference 
SUVL-AmBisome 17 13 (77) Mills et aIs 
SUVL-AmBisome 32 21 (66) Ringden et aI@ 
SUVL-AmBisome 5 3 (60) Chopra et aIs 
ABCD 32 11 (34) Oppenheim et aIs 
ABCD 82 40 (49) White et alz2 
ABLC 133+ 63 (47) Walsh et aIs 
ABLC 16+ 11 (69) ListerB5 
*Success or improvement; tpatients who had failed to respond to at least 500 
mg cumulative dose of prior conventional amphotericin B. ABCD = 
amphotericin B colloidal dispersion; ABLC = amphotericin B lipid complex. 
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response rate was significantly higher with ABCD com- 
pared to DAMB (49% and 23%, respectively; P < O.OOl), 
and patients treated with the lipid preparation also expe- 
rienced significantly less nephrotoxicity (S% vs. 43%; P < 
0.001). There is a problem in the evaluation of these stud- 
ies. The high variability in the diagnostic criteria of 
aspergillosis could have introduced a bias in the defini- 
tion of success or failure in the different trials, thus influ- 
encing the “success” rates and providing obvious 
difficulties in the interpretation of the “real” efficacy of 
the treatment, even when using a pragmatic criterium, 
such as survival. 
Fusariosis. The mortality rate among patients with fusar- 
iosis treated with DAMB remains high. Within the Amer- 
ican open-label protocol using ABLC, however, 9 (82%) 
of 11 patients treated achieved a clinical response (see 
Table 6).59 This is a promising result, that needs to be 
confirmed in larger populations. Indeed, survival from 
disseminated fusariosis seems to be correlated to bone 
marrow recovery rather than to any kind of antifungal 
therapy. 
Other Infections. In the American open-label protocol 
with ABLC, there were high clinical response rates 
among patients with cryptococcosis, zygomycosis, or 
other fungal infection (see Tables 6 and 7).56,61 Only a 
few patients with mucormycosis have been treated with 
lipid-based forms of amphotericin B, and most of these 
treatments have been successful,65 although again it 
should be remembered that much larger patient num- 
bers are required before definitive conclusions can be 
drawn. 
Empirical Antifungal Therapy 
The use of empirical antifungal therapy in persistently 
febrile granulocytopenic cancer patients, including those 
receiving BMT, is a popular procedure, even if validated 
by an observational study and by only one randomized 
clinical trial performed in a small patient population.34@ 
Deoxycholate amphotericin B is considered the drug of 
choice for this indication, even if other antifungal drugs, 
such as fluconazole, might be effective in selected 
cases.14,69 Recently, two randomized studies demonstrated 
that LAMB at 1 mg/kg per day was as effective as DAMB 
for this indication.“*‘l In the study by Walsh and cowork- 
er’s,‘l 687 persistently febrile and neutropenic patients 
received either LAMB or DAMB according to a double- 
blind, randomized design. The two groups of patients had 
similar response rates, in terms of survival and rate of 
defervescence. Patients receiving DAMB experienced a 
higher rate of infusion-related fevers (44% vs. 17%), 
episodes of chills and rigors (54% vs. IS%), cardiorespi- 
ratory events (46% vs. 13%) and nephrotoxicity (34% vs. 
19%). The authors also reported a higher incidence of 
breakthrough fungal infections in patients receiving 
DAME. 
CONCLUSIONS 
In terms of tolerance, the lipid-based compounds are bet- 
ter tolerated than DAMB, especially because of their 
reduced renal toxicity. In terms of efficacy, data suggest 
possible equivalence, although few randomized clinical 
trials have been performed. The relative merits of the 
three formulations in terms of comparative efficacy and 
toxicity are still unknown, since no comparative trial is 
available. Unfortunately, the acquisition cost of the lipid 
compounds is far higher than that of DAMB, both because 
of the intrinsic cost of the drugs and because of the much 
higher dose required. Costs based on the British National 
Formulary of the available packages of lipid-based ampho- 
tericin B compounds in the United Kingdom per 100 mg 
are approximately US$136.7 for ABLC, ~~$464 for LAMB, 
and US$318.4 for ABCD.” According to the 58th Edition 
of the Italian Directory of Drugs and Manufacturers,73 the 
costs in US$for 100 mg of ABLC, LAMB, and ABCD 
(including the 50% discount on the official cost that drug 
companies use to apply when selling drugs to public 
institutions) are about US$lZS, US$358, and ~~$296 (dol- 
lar rate of July 23,1998), thus slightly different from the 
prices in the United Kingdom. The administration sched- 
ules approved for the three lipidic compounds are dif- 
ferent: ABLC is approved at 5 mg/kg per day, SUVL-AmB 
is approved at 3 mg/kg per day, and ABCD is approved 
at 4 mg/kg per day. This might introduce further differ- 
ences in terms of cost. However, it is unclear why the 
three compounds should be used at different dosages. 
Indeed, animal models have shown that the three com- 
pounds are equipotent on a per milligram basis and prob- 
ably 5 mg/kg per day is the most reasonable dosage, at 
least in documented aspergillosis.*’ 
In light of these considerations and waiting for more 
information about the relative merits of the lipid com- 
pounds (especially among themselves), we believe that 
the lipid formulations of amphotericin B must be con- 
sidered as an alternative in selected patients with a doc- 
umented fungal infection that can only be treated with 
amphotericin B. These include patients whose renal func- 
tion is primarily or secondarily (after DAMB therapy) 
severely compromised and those with untreatable imme- 
diate side effects (e.g., bronchospasm). At the time of 
writing, the choice of the lipid-based formulation cannot 
be based on data from comparative clinical trials, but only 
on the ratio between dosage and cost and, perhaps, on 
data coming from animal models. Further randomized 
studies are needed to determine whether administration 
of these new agents will improve outcome, and to deter- 
mine the optimal dosage in terms of maximal efficacy 
with minimal toxicity and minimal costs, in both adults 
and children. Moreover, a better knowledge of the dif- 
ferent human pharmacokinetic properties of the three 
lipid-based compounds of amphotericin B might allow 
physicians to choose the appropriate compound accord- 
ing to the localization of the infection. 
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